ReddingiusR.E., SchröderC.H., MonnensL.A.H.Intraperitoneal administration of recombinant human erythropoietin in children on continuous ambulatory peritoneal dialysis.Eur J Pediatr1992; 151: 540–2.
2.
KauszT.A., WatkinsS.L., HanseC., GodwinD.A., PalmerR.B., BrandtJ.R.Intraperitoneal erythropoietin in children on peritoneal dialysis: a study of pharmacokinetics and efficacy.Am J Kidney Dis1999; 34: 651–6.
3.
BrandtJ.R., AvnerE.D., HickmanR.O., WatkinsS.L.Safety and efficacy of erythropoietin in children with chronic renal failure.Pediatr Nephrol1999; 13: 143–7.
4.
Van Damme–LombaertsR., HermanJ.Erythropoietin treatment in children with renal failure.Pediatr Nephrol1999; 13: 148–52.
5.
ReddingiusR.E., De BoerA.W., SchröderC.H., WillemsJ.L., MonnensL.A.H.Increase of the bioavailability of intraperitoneal erythropoietin in children on peritoneal dialysis by administration in small dialysis bags.Perit Dial Int1997; 17: 467–70.
6.
ReddingiusR.E., SchröderC.H., KosterA.M., MonnensL.A.H.Pharmacokinetics of recombinant human erythropoietin in children treated with continuous ambulatory peritoneal dialysis.Eur J Pediatr1994; 153: 850–4.
JohnsonC.A., WakeenM., TaylorC.A.III, ZimmermanS.W., BurkartJ., BhattacharyaA.Comparison of intraperitoneal and subcutaneous epoetin alfa in peritoneal dialysis patients.Perit Dial Int1999; 19: 578–82.
9.
TaylorC.A.III, KosorokM.R., ZimmermanS.W., JohnsonC.A.Pharmacokinetics of intraperitoneal epoetin alfa in patients on peritoneal dialysis using an 8-hour “dry dwell” dosing technique.Am J Kidney Dis1999; 34: 657–62.
